FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2001
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 for the transition period from __________ to ________.
COMMISSION FILE NUMBER: 0-30859
-------
CARESCIENCE, INC.
------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
PENNSYLVANIA 23-2703715
--------------------------------- -------------------
(STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER
OF INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
3600 MARKET STREET
PHILADELPHIA, PA 19104
----------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(ZIP CODE)
(215) 387-9401
----------------------------------------------------
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
----------------------------------------------------
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR,
IF CHANGED SINCE LAST REPORT)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
The number of shares of the registrant's Common Stock outstanding, as of
May 11, 2001 was 13,016,851.
Page 1
CARESCIENCE INC.
FORM 10-Q
March 31, 2001
INDEX
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets--December 31, 2000 and March 31,
2001 (unaudited)............................................................2
Consolidated Statements of Operations--Three Months Ended March 31,
2000 and March 31, 2001 (unaudited).........................................3
Consolidated Statements of Cash Flows--Three Months Ended March 31, 2000
and March 31, 2001 (unaudited)..............................................4
Notes to Consolidated Financial Statements....................................5
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations...................................................8
Item 3. Quantitative and Qualitative Disclosures About Market Risk...........12
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds.............................12
Item 6. Exhibits and Reports on Form 8-K......................................12
Page 2
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
CARESCIENCE, INC.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, MARCH 31,
2000 2001
------------ ------------
(UNAUDITED)
ASSETS
Current assets:
Cash and cash equivalents ............................. $ 26,702,096 $ 26,058,580
Short-term investments ................................ 3,001,770 --
Interest receivable ................................... 174,034 55,314
Accounts receivable, net of allowance for doubtful
accounts of $48,794 and $54,269, respectively ...... 865,075 1,175,663
Prepaid expenses and other ............................ 240,345 278,033
------------ ------------
Total current assets .................................... 30,983,320 27,567,590
------------ ------------
Property and equipment:
Computer equipment .................................... 4,611,573 4,720,124
Office equipment ...................................... 482,385 485,596
Furniture and fixtures ................................ 397,629 397,629
------------ ------------
5,491,587 5,603,349
Less--Accumulated depreciation and amortization ....... (2,562,342) (3,017,211)
------------ ------------
Net property and equipment .......................... 2,929,245 2,586,138
------------ ------------
Goodwill and other intangibles, net ................. -- 1,429,116
------------ ------------
Total assets ...................................... $ 33,912,565 $ 31,582,844
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of capital lease obligations and
notes payable ....................................... $ 250,685 $ 293,342
Accounts payable ...................................... 1,090,613 481,354
Accrued expenses ...................................... 1,141,662 1,024,142
Deferred revenues ..................................... 3,035,511 4,336,758
------------ ------------
Total current liabilities ........................... 5,518,471 6,135,596
------------ ------------
Capital lease obligations ............................... 428,602 368,732
------------ ------------
Shareholders' equity:
Common stock, no par value, 16,000,000 shares
authorized, 14,206,851 and 14,456,851 shares issued
and 12,766,851 and 13,016,851 outstanding ........... 59,612,380 59,831,130
Additional paid-in capital ............................ 5,590,620 5,357,717
Deferred compensation ................................. (4,010,828) (3,461,905)
Accumulated other comprehensive income ................ 1,770 --
Accumulated deficit ................................... (32,328,450) (35,748,426)
Treasury stock, at cost, 1,440,000 shares ............. (900,000) (900,000)
------------ ------------
Total shareholders' equity .......................... 27,965,492 25,078,516
------------ ------------
Total liabilities and shareholders' equity ........ $ 33,912,565 $ 31,582,844
============ ============
The accompanying notes are an integral part of these statements
Page 3
CARESCIENCE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED
MARCH 31,
-------------------------------
2000 2001
------------ ------------
(UNAUDITED)
Revenues .............................. $ 1,628,927 $ 2,515,611
Cost of revenues (excludes stock-based
compensation of $170,131 and
$163,413, respectively) ............. 1,026,041 1,372,364
------------ ------------
Gross profit ........................ 602,886 1,143,247
------------ ------------
Operating expenses:
Research and development (excludes
stock-based compensation of $22,965
and $9,772, respectively) ......... 599,123 1,298,242
Selling, general and administrative
(excludes stock-based compensation
of $145,928 and $142,835,
respectively) ..................... 1,564,739 3,311,022
Stock-based compensation ............ 339,024 316,020
------------ ------------
Total operating expenses .......... 2,502,886 4,925,284
------------ ------------
Operating loss .................... (1,900,000) (3,782,037)
Interest income ....................... (42,048) (383,608)
Interest expense ...................... 20,840 21,547
------------ ------------
Net loss .............................. (1,878,792) (3,419,976)
Accretion of redemption premium on
preferred stock ..................... 115,371 --
------------ ------------
Net loss applicable to common
shareholders ........................ $ (1,994,163) $ (3,419,976)
============ ============
Net loss per common share:
Basic and diluted ................... $ (0.59) $ (0.26)
Weighted average shares outstanding:
Basic and diluted ................... 3,387,900 12,985,952
The accompanying notes are an integral part of these statements.
Page 4
CARESCIENCE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED
MARCH 31,
-------------------------------
2000 2001
------------ ------------
(UNAUDITED)
Cash flows from operating activities:
Net loss ........................................... $ (1,878,792) $ (3,419,976)
Adjustments to reconcile net loss to net cash
used in operating activities--
Depreciation and amortization .................. 146,192 325,468
Loss on disposal ............................... -- 158,000
Provision for bad debts ........................ 9,000 5,475
Stock-based compensation ....................... 339,024 316,020
Changes in assets and liabilities--
(Increase) decrease in--
Interest receivable ........................ -- 118,605
Accounts receivable ........................ 2,131 (107,121)
Prepaid expenses and other ................. (411,865) (35,748)
Increase (decrease) in--
Accounts payable and accrued expenses ...... 1,107,632 (870,453)
Deferred revenues .......................... (401,348) 890,957
------------ ------------
Net cash used in operating activities ...... (1,088,026) (2,618,773)
------------ ------------
Cash flows (used in) provided by investing activities:
Proceeds form the redemption of short-term
investments ...................................... -- 3,000,115
Purchase of acquisition, net ....................... -- (882,367)
Purchases of property and equipment, net ........... (192,037) (75,247)
------------ ------------
Net cash (used in) providing by
investing activities ..................... (192,037) 2,042,501
------------ ------------
Cash flows used in financing activities:
Payments on capital lease obligations .............. (98,280) (67,244)
------------ ------------
Net decrease in cash and cash equivalents ............ (1,378,343) (643,516)
Cash and cash equivalents, beginning of period ....... 3,381,600 26,702,096
------------ ------------
Cash and cash equivalents, end of period ............. $ 2,003,257 $ 26,058,580
============ ============
The accompanying notes are an integral part of these statements.
Page 5
CARESCIENCE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization and Basis of Presentation
CareScience, Inc. (formerly Care Management Science Corporation) provides
Internet-based tools designed to improve the quality and efficiency of health
care. The Company uses its proprietary clinical algorithms and data collection
and storage technologies to perform complex clinical analyses. The Company's
customers use its services to identify clinical inefficiencies and medical
errors and monitor the results of implemented solutions. Additionally, the
Company facilitates the real-time exchange of clinical information over the
Internet among local health care constituents.
The consolidated balance sheet as of March 31, 2001, the consolidated
statements of operations for the three months ended March 31, 2000 and 2001 and
the consolidated statements of cash flows for the three months ended March 31,
2000 and 2001 have been prepared by the Company without audit. In the opinion of
management, all adjustments, consisting of normal and recurring adjustments,
necessary to present fairly the financial position, results of operations and
cash flows at March 31, 2001 and for all periods presented have been made.
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. It is suggested that these financial statements
be read in conjunction with the financial statements and notes thereto included
in the Annual Report on Form 10-K as filed with the Securities and Exchange
Commission. The results of operations for the three months ended March 31, 2001
are not necessarily indicative of the operating results for the full year.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of
CareScience, Inc. and its subsidiary. All significant intercompany transactions
and balances have been eliminated.
Cash and Cash Equivalents and Short-term Investments
The Company invests excess cash in highly liquid investment-grade
marketable securities including corporate commercial paper and U.S. government
agency bonds. For financial reporting purposes, the Company considers all highly
liquid investment instruments purchased with an original maturity of three
months or less to be cash equivalents. All investment instruments with
maturities greater than three months are available for use in current operations
and accordingly are classified as current assets. All investments are considered
available-for-sale and accordingly, unrealized gains and losses are included in
a separate component of shareholders' equity.
Page 6
As of December 31, 2000 and March 31, 2001 cash and cash equivalents and
short-term investments at cost and fair market value consisted of the following:
DECEMBER 31, 2000
---------------------------------------------
GROSS FAIR
ORIGINAL UNREALIZED MARKET
COST GAINS VALUE
----------- ----------- -----------
Cash and cash equivalents $26,702,096 $ -- $26,702,096
Short-term investments 3,000,000 1,770 3,001,770
----------- ----------- -----------
$29,702,096 $ 1,770 $29,703,866
=========== =========== ===========
MARCH 31, 2001
---------------------------------------------
(UNAUDITED)
GROSS FAIR
ORIGINAL UNREALIZED MARKET
COST GAINS VALUE
----------- ----------- -----------
Cash and cash equivalents $26,058,580 $ -- $26,058,580
Short-term investments -- -- --
----------- ----------- -----------
$26,058,580 $ $26,058,580
=========== =========== ===========
At December 31, 2000 short-term investments consists of one debt instrument
maturing November 6, 2002 which was redeemed February 6, 2001.
Supplemental Cash Flow Information
The Company paid interest of $20,840 and $21,547 for the three months ended
March 31, 2000 and 2001, respectively.
The Company financed $94,511 and $0 of property and equipment purchases
with capital leases for the three months ended March 31, 2000 and 2001,
respectively.
Major Customers
The Company's operations are conducted in one business segment and sales
are primarily made to health care payors and providers. The company had one
customer for each of the three month periods ended March 31, 2000 and 2001,
which accounted for 24% and 15% of total revenues, respectively.
The Company had one customer at March 31, 2001, which accounted for 10% of
total accounts receivable.
(2) NET LOSS PER SHARE
Net loss per share is calculated utilizing the principles of SFAS No. 128,
"Earnings per Share" ("EPS"). Basic EPS excludes potentially dilutive securities
and is computed by dividing net income available to common shareholders by the
weighted-average number of common shares outstanding for the period. Diluted EPS
is computed assuming the conversion or exercise of all dilutive securities such
as Preferred stock, options and warrants.
Under SFAS No. 128, the Company's granting of certain stock options,
warrants and convertible Preferred stock resulted in potential dilution of basic
EPS. The number of incremental shares from the assumed exercise of stock options
and warrants is calculated applying the treasury stock method. Stock options,
warrants and Preferred stock convertible into common shares were excluded from
the calculations as they were anti-dilutive due to the net loss.
Page 7
(3) COMMON STOCK OPTIONS
Equity Compensation Plans
The Company's 1995 Equity Compensation Plan (the "Plan") permits the
granting of incentive stock options, nonqualified stock options, stock
appreciation rights and restricted stock. The Company has authorized the
issuance of up to 2,065,038 shares of Common stock to satisfy grants under the
Plan. At March 31, 2001, there were 641,012 shares reserved under the Plan
available for grant. A committee of the Board of Directors (the "Committee")
administers the Plan and determines the terms of the grants.
In December 1998, the Company adopted the 1998 Time Accelerated Restricted
Stock Option Plan (the "Accelerated Plan"). The Accelerated Plan provides for
the granting of non-qualified stock options to officers, senior management and
employee directors of the Company. The aggregate number of shares of Common
stock the Company may issue under the Accelerated Plan is 483,594 shares. At
March 31, 2001 there were no shares reserved under the Accelerated Plan
available for grant.
The Company accounts for all plans under APB Opinion No. 25, under which
compensation expense is recognized based on the amount by which the fair value
of the underlying common stock exceeds the exercise price of the stock options
on the measurement date. For financial reporting purposes, the Company has
determined that the deemed fair market value on the measurement date for certain
stock options was in excess of the exercise price. This amount has been recorded
as deferred compensation and is being amortized over the vesting period of the
applicable options, which range between four and seven years. The Company
recorded deferred compensation of $120,683 and $0 during the year ended December
31, 2000 and the three months ended March 31, 2001, respectively, and reversed
$154,902 and $232,903 of deferred compensation in connection with forfeited
common stock options during the year ended December 31, 2000 and three months
ended March 31, 2001, respectively. The Company recognized $339,024 and $316,020
of compensation expense related to options for the three months ended March 31,
2000 and 2001, respectively.
The following table summarizes the option activity for both plans:
OPTIONS OUTSTANDING
---------------------------------------------------
SHARES WEIGHTED
AVAILABLE NUMBER EXERCISE AVERAGE
FOR OF PRICE AGGREGATE EXERCISE
GRANT SHARES PER SHARE PRICE PRICE
---------- --------- ----------- ---------- ---------
Balance, December 31, 1997............. 362,800 251,200 $0.25- 1.25 $271,200 $1.08
Authorized........................... 1,134,632 -- -- -- --
Granted.............................. (472,635) 472,635 1.25- 2.60 895,227 1.89
Forfeited/Canceled .................. 12,800 (12,800) 0.25- 1.25 (10,800) .84
---------- --------- ----------- ---------- -----
Balance, December 31, 1998............. 1,037,597 711,035 0.25- 2.60 1,155,627 1.63
Authorized........................... -- -- -- -- --
Granted.............................. (1,108,150) 1,108,150 1.25- 2.59 2,814,164 2.54
Forfeited/Canceled................... 216,413 (216,413) 0.25- 2.59 (291,017) 1.34
---------- --------- ----------- ---------- -----
Balance, December 31, 1999............. 145,860 1,602,772 0.25- 2.60 3,678,774 2.30
Authorized........................... 800,000 -- -- -- --
Granted.............................. (817,663) 817,663 0.78-12.00 6,782,592 8.30
Exercised............................ -- (10,000) 0.25 2,500 0.25
Forfeited/Canceled .................. 573,298 (573,298) 1.25-12.00 (4,926,524) 8.59
---------- --------- ----------- ---------- -----
Balance, December 31, 2000............. 701,495 1,837,137 0.25-12.00 5,537,342 3.01
Authorized (unaudited)............... -- -- -- -- --
Granted (unaudited).................. (144,236) 144,236 0.88- 2.81 156,443 1.08
Forfeited/Canceled (unaudited)....... 83,753 (83,753) 0.78- 6.63 (284,153) 3.39
---------- --------- ----------- ---------- -----
Balance, March 31, 2001(unaudited)..... 641,012 1,897,620 $0.25-12.00 $5,409,632 $2.85
========== ========= =========== ========== =====
Page 8
(4) Acquisition of Business
On January 12, 2001, the Company acquired substantially all of the assets
and certain liabilities of Strategic Outcomes Services, Inc. (SOS), a
pharmacoeconomic consulting company located in North Carolina. The total
purchase price was approximately $1.3 million which included a cash payment of
$1.1 million and 250,000 shares of Common stock valued at $218,750 or $0.88 a
share. The purchase agreement also provides for additional contingent payments
based on achieving revenue and profitability milestones as defined. The
transaction was accounted for using the purchase method of accounting. A summary
of the assets acquired and liabilities assumed in the acquisition follows:
Estimated fair values:
Cash $ 217,632
Other current assets 210,882
Equipment 36,515
Current Liabilities (603,995)
Goodwill and other intangibles 1,457,715
-----------
Purchase price 1,318,749
Less cash acquired and stock issued (436,382)
-----------
Net cash paid $ 882,367
===========
The allocation of the purchase price is preliminary. The Company is currently
amortizing goodwill and other intangibles on a straight-line basis over a period
of eight years. The Company is in the process of allocating the excess purchase
price, including the determination of the useful lives of the intangible assets.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
This report includes a number of forward-looking statements that reflect
our current views with respect to future events and financial performance. We
use words such as anticipates, believes, expects, future, intends, and similar
expressions to identify forward-looking statements. For these statements we
claim the protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995. There are important
factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements, including:
- the difficulty in evaluating our business because we operate in a new
industry and our operating history is limited;
- we have a history of losses and expect our losses to continue;
- the proprietary technology we own or license may be subjected to
infringement claims or disagreements with the licensor which could be
costly to resolve;
- we depend on an exclusive license with the University of Pennsylvania for
our technology, and the loss of this license would impair our ability to
develop our business;
- we could be liable for information retrieved from our Web sites and incur
significant costs from resulting claims;
- we may experience system failures which could interrupt our service and
damage our customer relationships;
- the health care industry may not accept our solutions or buy our services
which would adversely affect our financial results;
- because our revenues are dependent on a limited number of services, the
failure of any one of these services would significantly decrease our
revenues;
- termination of one or more of our significant contracts would cause a
significant decline in our revenue;
Page 9
- failure to manage our growth would adversely affect our operations;
- we face intense competition and may be unable to compete successfully which
would adversely effect our financial results;
- the loss of any of our key personnel could adversely affect our operations;
- our failure to develop strategic relationships could adversely affect our
ability to develop new services;
- our failure to use new technologies effectively or to adapt emerging
industry standards would adversely affect our ability to compete;
- our failure to adapt our technology to our customers' needs or to handle
high levels of customer activity would adversely affect our ability to
increase revenue;
- failure of our service providers could interrupt our business and damage
our customer relationships;
- we may need to obtain additional capital and failure to do so may limit our
growth;
- health information is subject to potential government regulation and legal
uncertainties and changes may require us to alter our business;
- changes in the health care industry could adversely affect our operations;
- our business will suffer if commercial users do not accept Internet
solutions;
- our industry is evolving and we may not adapt successfully.
Overview
CareScience, Inc. is a provider of online care management services. Our
mission is to transform the quality and efficiency of care delivery by providing
innovative clinical information technology to the health care industry. We
market our services to hospitals, health systems and pharmaceutical and
biotechnology manufacturers, and support more than 150 customers in 40 states
and in Europe.
We work with health care providers to manage clinical processes surrounding
the point of care so that fundamental reductions in errors and operating cost
can be achieved. Our products collect, share, store and analyze clinical data
generated by more than 100 widely used health information systems. Our services
allow customers to apply this data to the management of care, including quality
monitoring, practice improvement, credentialing, profiling, error tracking, case
management and clinical guidelines. We provide consulting services to healthcare
providers that support strategic planning and clinical operations, with a
special emphasis on mentoring physicians and other clinical leaders in
operational and executive roles.
For the pharmaceutical and biotechnology industry, we provide tools and
services that shorten the drug development cycle and improve development yield.
Our offerings include a suite of Internet-based data analysis and workflow
management tools, consulting services, customized research and strategic
development support. These tools and services are aimed at the specialized drug
development needs of pharmaceutical industry clinicians, product managers,
market strategists, health economists and outcomes researchers.
We have pioneered and commercialized numerous clinical information
technologies. We have developed one of the nation's first online quality
measurement and management tools, one of the first clinically based outcome risk
assessment algorithms, one of the first health care application service
providers, and, most recently, the first peer-to-peer clinical data sharing
technology. We have developed these tools in collaboration with leading public
organizations, including the Wharton School of Business at the University of
Pennsylvania, the National Library of Medicine, Los Alamos National Laboratory
and The California HealthCare Foundation.
CareScience was incorporated in 1992 with the purpose of commercializing
intellectual property that was developed at the University of Pennsylvania
School of Medicine and The Wharton School of Business. In 1993, we exclusively
licensed the intellectual property underlying our core technology in a 30-
Page 10
year agreement with the University of Pennsylvania. In 1996, we launched
our first Internet-based commercial product based on this proprietary technology
under our Care Management System-TM- (formerly called CaduCIS) product line. In
1999, we launched our Care Data Exchange-TM-, and Technology Assessment
Tools-TM-, as well as our Lifecycle Decision System-TM- product line, which is
aimed at the pharmaceutical and biotechnology industries. To date, we have
signed more than 50 contracts covering more than 150 hospitals, health systems
and pharmaceutical companies. On March 7, 2000, we changed our name from Care
Management Science Corporation to CareScience, Inc.
We generate revenues from subscriptions to our Internet-based proprietary
technology applications and hosting of customer data, as well as from training,
implementation and consulting services. We sell our services individually or as
an integrated suite of services. Our contracts are fixed price based on
estimates of certain variables, such as the number of a hospital's patient
admissions or outpatient visits.
Our subscription and development agreements typically cover an initial
three-to five-year period with provisions for automatic renewals. We recognize
training and implementation fees, as well as subscriptions and related hosting
revenues, on a pro-rata basis over the life of the contract. We recognize
consulting fees on a percentage-of-completion basis or as the program or service
is delivered.
Our contracts generally provide for payment in advance of services
rendered. Therefore, we record these payments as deferred revenues and recognize
these payments when earned in accordance with our revenue recognition policy.
Our deferred revenue balances were $3.0 million and $4.3 million at December 31,
2000 and March 31, 2001, respectively.
We have incurred substantial research and development costs since inception
and have also invested in our corporate infrastructure to support our long-term
growth strategy. We expect that our operating expenses will continue to increase
as we expand our product development and sales and marketing efforts.
Accordingly, we expect to continue to incur quarterly net losses for the
foreseeable future.
On June 28, 2000 we completed an initial public offering of 4,000,000
shares of Common stock at a price of $12.00 per share. We received aggregate net
cash proceeds of approximately $43.4 million from the initial public offering on
July 5, 2000.
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2001 AND MARCH 31, 2000
REVENUES
Total revenues increased 54% to $2.5 million for the three months ended
March 31, 2001 from $1.6 million for the three months ended March 31, 2000. The
increase was primarily related to revenues generated from newly signed customer
and development contracts.
Unrecognized revenues related to customer and development contracts as of
March 31, 2001 totaled $16.3 million.
COST OF REVENUES
Cost of revenues include customer and service-related costs including
personnel and facility costs, depreciation and maintenance. Cost of revenues for
the three months ended March 31, 2001 was $1.3 million (excluding stock-based
compensation of $163,000), an increase of $346,000 or 34%, compared to $1.0
million (excluding stock-based compensation of $170,000) for the three months
ended March 31, 2000. The increase was primarily a result of additional costs
necessary to service new customers.
GROSS PROFIT
Our gross profit margin increased from 37% for the three months ended March
31, 2000, to 45% for the three months ended March 31, 2001. The increase in
gross profit margin is primarily due to increased revenues spread over a fixed
base of costs.
Page 11
RESEARCH AND DEVELOPMENT
Research and development costs include technology and product development
costs. Research and development costs for the three months ended March 31, 2001
were $1.3 million (excluding stock-based compensation of $10,000), an increase
of $699,000 or approximately 117%, compared to $599,000 (excluding stock based
compensation) for the three months ended March 31, 2000. This increase is
primarily due to expenditures made related to new development efforts.
As a percentage of revenue, research and development costs were 52% for the
three months ended March 31, 2001 as compared to 37% for the three months ended
March 31, 2000. This increase for 2000 to 2001 reflects increased expenditures
made related to new development efforts.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses include costs associated with
our sales, marketing, finance, human resource and administrative functions.
Selling, general and administrative expenses for the three months ended March
31, 2001 were $3.3 million (excluding stock-based compensation of $143,000), an
increase of $1.7 million, or 112% compared to $1.6 million (excluding stock
based compensation of $146,000) for the three months ended March 31, 2000. The
increase was primarily related to hiring of additional sales and management
personnel and marketing expenditures to increase and support customer growth.
As a percentage of revenues, selling, general, and administrative expenses
were 132% for the three months ended March 31, 2001 as compared to 96% for the
three months ended March 31, 2000. The increase from 2000 to 2001 reflects the
additional expenditures related to personnel and other marketing activities.
STOCK-BASED COMPENSATION
We granted certain stock options to our officers and employees with
exercise prices deemed to be below the fair market value of the underlying
stock. The remaining cumulative difference between the fair value of the
underlying stock at the date the options were granted and the exercise price of
the granted options was $3.5 million at March 31, 2001. We expect to amortize
this amount over the four to seven year vesting periods of the granted options.
Accordingly, our results from operations will include stock-based compensation
expense at least through 2006. We recognized $339,000 and $316,000 of this
expense during the three months ended March 31, 2000, and 2001, respectively.
INTEREST INCOME AND EXPENSE
Net interest income for the three months ended March 31, 2001was $362,000,
an increase of $341,000, compared to $21,000 for the three months ended March
31, 2000. The increase is primarily due to higher investable cash balances as a
result of the initial public offering.
LIQUIDITY AND CAPITAL RESOURCES - MARCH 31, 2001
Since inception, we have financed our operations and funded our capital
expenditures through the private sale of equity securities, supplemented by
private debt and equipment leases. We believe that proceeds from our initial
public offering will be sufficient to fund anticipated capital expenditures and
working capital requirement for at least the next 12 months. As of March 31,
2001, we had $26.1 million in cash and working capital of $21.4 million.
Net cash used in operating activities was $2.6 million for the three months
ended March 31, 2001 and $1.1 million for the three months ended March 31, 2000.
For those periods, net cash used in operating activities was primarily to fund
losses from operations.
Net cash provided by investing activities was $2.0 million for the three
months ended March 31, 2001 and consisted primarily of proceeds from the
redemption of short-term investments net of purchases of property and equipment.
Net cash used in financing activities was $192,000 for the three months ended
March 31, 2000 and consisted of purchases of property and equipment.
Page 12
Net cash used in financing activities was $67,000 for the three months
ended March 31, 2001 and $98,000 for three months ended March 31, 2000, and
consisted primarily of payments on capital lease obligations.
As we execute our strategy, we expect significant increases in our
operating expenses to fund development of current and new divisions and product
lines. Presently, we anticipate that our existing capital resources and the
proceeds from the offering will meet our operating and investing needs through
the end of 2002. After that time, additional funding may not be available on
acceptable terms or at all. If we require additional capital resources to grow
our business, execute our operating plans for acquire complementary businesses
as any time in the future, we may seek to sell additional equity or debt
securities or secure additional lines of credit, which may result in ownership
dilution to our shareholders.
ITEM 3. QUANTITIATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our cash equivalents, short-term investments and capital lease obligations
are at fixed interest rates and therefore the fair market value of these
instruments is affected by changes in market interest rates. As of March 31,
2001 all of our cash equivalents matured within 6 months and we had the ability
to immediately liquidate our investments. Therefore, we believe that we are
exposed to immaterial levels of market risk.
PART II. OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
SALES OF UNREGISTERED SECURITIES
On January 12, 2001, in connection with the acquisition of Strategic
Outcomes Services, Inc. ("SOS"), we issued 250,000 shares of our Common stock to
the 19 shareholders of SOS. Such sales were made in reliance upon the exemption
provided by Section 4(2) of the Securities Act for transactions not involving a
public offering and/or Rule 701 under the Securities Act.
USE OF PROCEEDS
On June 28, 2000 the Securities and Exchange Commission declared effective
our Registration Statement on Form S-1 (File number 333-32376), relating to the
initial public offering of our Common Stock, no par value per share. The net
offering proceeds to us after total expenses were $43.2 million. As of March 31,
2001, we have used approximately $17.8 million of the net proceeds from our
initial public offering of which approximately $8.4 million was used for working
capital and other general corporate purposes, approximately $6.5 million was
used for dividends on and the redemption of preferred stock, approximately $1.8
million was used for the purchase of property plant and equipment and $1.1
million was used for the acquisition of Strategic Outcomes Services, Inc.,
None of the net proceeds from the offering were used to pay, directly or
indirectly, directors, officers, persons owning ten percent or more of the
Company's equity securities, or affiliates of the Company.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
See Exhibit Index
(b) Reports on Form 8-K
January 22, 2001 to report Other Events under Item 5 of Form 8-K.
Page 13
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CARESCIENCE, INC.
Date: May 11, 2001 By: /s/ RONALD A. PAULUS
-------------------------------
Ronald A. Paulus, President
Date: May 11, 2001 By: /s/ STEVEN BELL
-------------------------------
Steven Bell, Chief Financial
Officer and Treasurer
Page 14
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------